Kansas Lawmakers Debate Healthcare Access Expansion
In Kansas, there’s a heated discussion among lawmakers about expanding healthcare access through the Federal 340B Drug Pricing Program. If Senate Bill 284 moves forward, it could potentially empower large hospital chains at the expense of consumer choice. This change would exacerbate existing challenges within the program, such as accountability issues, rising costs, and market concentration, ultimately not benefitting the patients it was designed to support.
The 340B program, initiated in 1992, aimed to assist safety-net providers catering to uninsured and low-income patients by mandating drug companies to sell medications at significant discounts. Today, it stands as the second largest prescription drug purchasing program in the U.S., behind Medicare Part D, with an estimated cost of $66.3 billion in 2023.
As stated, “The 340B program is no longer achieving its stated objectives. This increases industry consolidation, drives up costs, and reduces access to care, especially in rural areas.”
Senate Bill 284 could worsen the situation. This legislation proposes to prohibit drug manufacturers from denying access to specific medications, diminish transparency, and hinder innovation. It raises concerns about hospitals potentially exploiting the program, rather than addressing the underlying issues that inflate costs for Kansans, small businesses, and local healthcare providers.
The Illusion of 340B’s Benefits
Many believe that large health systems utilize the 340B advantages to bolster local hospitals, but that’s not quite the case. As the program has expanded, many rural hospitals have shuttered, adversely affecting communities. The law’s original intent—to fund drug purchases for clinics serving those in need—has been largely abandoned.
What began as a temporary safety net for at-risk populations has morphed into a lucrative revenue source for larger hospital systems. Nowadays, many 340B participants are affluent urban hospitals, cancer treatment centers, and institutions that provide limited charity care. When hospitals acquire outpatient clinics, they can claim eligibility for 340B regardless of the patient demographic, effectively charging full price to insurance companies while pocketing the difference from discounted drugs.
Multiple reports from federal agencies like the Government Accountability Office and the Office of the Inspector General highlight a lack of oversight regarding the program. Hospitals aren’t required to disclose how they utilize the substantial $340 billion in revenue or whether these savings benefit patients.
Wealth Disparity in Healthcare
Hospitals can buy medications at discounted rates, then charge significantly higher prices, keeping the profits to fund expansion instead of passing savings to patients. This reality fosters a trend of hospital integration nationwide, making it difficult for smaller, more efficient clinics to survive. They’re often compelled to sell to larger entities that enjoy heavy subsidies.
This trend spans hundreds of instances nationwide, inflating the overall spending by $340 billion, diverting essential resources from the low-income patients the program ultimately aimed to support. Since the accelerated abuse of the 340B program began in 2014, post-Affordable Care Act, nonprofit hospitals have engaged in aggressive acquisitions, raising prices and pushing independent providers out of the market.
Additionally, each participating hospital has the option to partner with numerous retail pharmacies, creating an expansive network that benefits from 340 billion yen in discounts while leaving needy patients behind. This reality leads to what’s referred to as “mission creep,” where programs originally established with altruism have turned into profit centers for a multibillion-dollar industry.
Instead of reducing costs, the 340B program introduces concealed subsidies that enrich institutions while obscuring healthcare prices. Adding to these concerns, some hospitals are utilizing the profits to fund abortion and gender transition services, navigating around the limits on federal funding for such procedures imposed by the Hyde Amendment.
Beyond Mere Preservation
Clearly, the 340B program has strayed from its original mission. It fuels industry consolidation, heightens costs, and hampers access to care, particularly in less accessible areas. Extending the program in Kansas could entrench a flawed system, plunging the state deeper into a cycle that serves hospitals over taxpayers.
Efforts are underway at the federal level, with Congress and the previous administration looking to reform 340B and Medicare to diminish waste and corruption. Kansas lawmakers would do well to follow suit. Instead of providing another boon to large hospital systems, the focus should be on reinstating accountability, fostering competition, and enhancing transparency to ensure healthcare prioritizes patients, not institutions.
